Altria sought authorization under an FDA pilot program, while regulatory risk tied to FDA statements is under scrutiny.
3 reports, 2 independent
Updated Sep 2
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Altria sought authorization under an FDA pilot program, while regulatory risk tied to FDA statements is under scrutiny.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Altria sued the FDA over its product review process and engaged in lobbying targeting Donald Trump.1 source
Altria applied to the FDA pilot program for authorization.1 source
Keep exploring
The entities involved
Related events
- The FDA's GRAS status allows supplements to bypass full review, a point targeted by Kennedy and analyzed by experts like Professor Cohen, involving Calley Means and Harvard Medical School.
- Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.
- Adam Craig reported positive results that could support FDA approval for a treatment.
- FDA failed to update warning labels despite confirmed risks associated with a product.
- FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.